| Zacks Company Profile for Senesco Technologies Inc. (ELOX : NSDQ) |
|
|
| |
| • Company Description |
| Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company's lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.
Number of Employees: 7 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $11.94 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 61,546 shares |
| Shares Outstanding: 0.69 (millions) |
| Market Capitalization: $8.22 (millions) |
| Beta: -1,891.27 |
| 52 Week High: $17.50 |
| 52 Week Low: $0.00 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
1.62% |
0.87% |
| 12 Week |
502.97% |
486.46% |
| Year To Date |
1,085,245.88% |
1,007,833.31% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Sumit Aggarwal - President; Chief Executive Officer and Director
Alan Walts - Chairman and Director
Daniel E. Geffken - Chief Financial Officer
Steven D. Rubin. - Director
Steven D. Rubin - Director
|
|
Peer Information
Senesco Technologies Inc. (CORR.)
Senesco Technologies Inc. (RSPI)
Senesco Technologies Inc. (CGXP)
Senesco Technologies Inc. (BGEN)
Senesco Technologies Inc. (GTBP)
Senesco Technologies Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 29014R301
SIC: 2836
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/26
Next Expected EPS Date: 08/03/26
|
|
Share - Related Items
Shares Outstanding: 0.69
Most Recent Split Date: 6.00 (0.09:1)
Beta: -1,891.27
Market Capitalization: $8.22 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $ |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/03/26 |
|
|
|
| |
